This is consistent with the findings of Travier et al. [47], who evaluated the impact of a 12-week exercise and diet program on metabolic risk in survivors with non-metastatic breast cancer, in which 81.1% of the patients were hormone receptor-positive and 62.2% were postmenopausal. The gene discussed is NR4A1; the disease is breast carcinoma.